KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Short-term Investments (2022 - 2025)

Historic Short-term Investments for Castle Biosciences (CSTL) over the last 4 years, with Q3 2025 value amounting to $202.0 million.

  • Castle Biosciences' Short-term Investments rose 929.2% to $202.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $202.0 million, marking a year-over-year increase of 929.2%. This contributed to the annual value of $173.4 million for FY2024, which is 2021.59% up from last year.
  • Latest data reveals that Castle Biosciences reported Short-term Investments of $202.0 million as of Q3 2025, which was up 929.2% from $193.7 million recorded in Q2 2025.
  • Castle Biosciences' Short-term Investments' 5-year high stood at $202.0 million during Q3 2025, with a 5-year trough of $117.2 million in Q1 2023.
  • Moreover, its 4-year median value for Short-term Investments was $156.3 million (2024), whereas its average is $159.0 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first soared by 510.46% in 2023, then surged by 3431.35% in 2024.
  • Quarter analysis of 4 years shows Castle Biosciences' Short-term Investments stood at $135.7 million in 2022, then rose by 6.32% to $144.3 million in 2023, then grew by 20.22% to $173.4 million in 2024, then increased by 16.48% to $202.0 million in 2025.
  • Its Short-term Investments was $202.0 million in Q3 2025, compared to $193.7 million in Q2 2025 and $185.5 million in Q1 2025.